Keywords: strong, data, 16-yr, follow-up, schering, ag, betaferon
Strong data from 16-yr follow-up of Schering AG's Betaferon
Article | 17 April 2006
German drugmaker Schering AG says that its multiple sclerosis drug Betaferon (interferon beta-1b) remained consistently safe, effective and well-tolerated ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
